Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar Disorder

Inclusion Criteria:

• Males and females age 6 to 17 with a diagnosis of current depression with bipolardisorder based on clinical assessment and confirmed by structured diagnostic interviewplus an initial Hamilton rating scale score >17 and a Young Mania Rating Score of <

• Children will only be allowed to participate in the trial if they have had moodstabilization on a steady dose of medication for at least 2 months. By moodstabilization we mean as determined by principle investigator, evaluator clinician,and as confirmed by KSADS.

• Subject and parent must have a level of understanding sufficient to communicateintelligently with the investigator and study coordinator, and to cooperate with alltests and examinations required by the protocol.

• Subjects and their legal representative must be considered reliable.

• Each subject and his/her authorized legal representative must understand the nature ofthe study. The subject's authorized legal representative must sign an informed consentdocument and the subject must sign an informed assent document.

• Subject must be able to participate in mandatory blood draws.

• Subject must be able to swallow pills.

Exclusion Criteria: Subjects with chronic medical illness, DSM-IV substance dependence within the past month,pregnant or nursing female subjects will be excluded from this study.

• Investigator and his/her immediate family; defined as the investigator's spouse,parent, child, grandparent, or grandchild.

• Serious, unstable illness including hepatic, renal, gastroenterological, respiratory,cardiovascular, endocrine, neurologic, immunologic, or hematologic disease.

• History of severe allergies or multiple adverse drug reactions.

• Non-febrile seizures without a clear and resolved etiology.

• Leukopenia or history of leukopenia without a clear and resolved etiology.

• Judged clinically to be at serious suicidal risk.

• Acute Psychosis

• Any other concomitant medication with primarily central nervous system activity otherthan specified in Concomitant Medication portion of the protocol.

• History of intolerance or non-response to bupropion.

• Treatment with nonreversible monoamine oxidase inhibitor within 2 weeks prior toinitiation of study.

• Current diagnosis of schizophrenia.

• History of head trauma

• CNS tumor

• Diabetic treated with oral hypoglycemics or insulin

• Current or prior diagnosis of bulimia or anorexia